Genedrive PLC Multi-partner grant awarded (8873C)
16 June 2023 - 4:00PM
UK Regulatory
TIDMGDR
RNS Number : 8873C
Genedrive PLC
16 June 2023
genedrive plc
("genedrive" or the "Company")
Multi-partner grant awarded for the validation of Genedrive(R)
CYP2C19 ID Kit in time critical NHS settings
Manchester NHS Industry partnership programme for rapid genomic
test implementation
genedrive plc (the "Company"), the point of care molecular
diagnostics company, today announces its participation in a
multi-partner grant award ("DEVOTE") from Innovate UK and the UK
government Innovation Accelerator programme with funding expected
to be made available to further the validation and implementation
of the new Genedrive(R) CYP2C19 ID Kit pharmacogenetic test in a
time critical clinical setting.
The Development and Validation of Technology for Time Critical
Genomic Testing (DEVOTE) grant will provide acute care patient
access and supporting infrastructure for the Company to assess the
real world clinical performance of time-critical clinical tests in
an NHS settings. The programme, led by the University of Manchester
(UoM), builds on the model of the previous successful UoM/genedrive
partnership with the PALOH programme, which supported the
development and evaluation of the Genedrive(R) MT-RNR1 ID Kit which
has recently received a recommendation from NICE.
DEVOTE pulls together health economists, clinicians,
informaticians, and researchers to quickly access new technologies,
and provide feedback in an iterative fashion. Genedrive's CYP2C19
ID Kit is one of three exemplar projects to be included in the
programme which is expected to be funded through the Innovate
grant, in-kind contributions, and other aligned funding. In the
main, funding is expected to go directly to the UoM and its NHS
partners to set up and coordinate the three projects, the total
amount of funding to be made available under the programme will be
determined in due course.
DEVOTE will focus on ischaemic stroke patients in acute care who
are targeted to be prescribed Clopidogrel to prevent further clot
formation. Clopidogrel is less efficacious in individuals with
certain genetic CYP2C19 variants because they do not metabolize
Clopidogrel effectively. Genedrive's CYP2C19 ID Kit is being
developed to provide guidance at the point of care on which
patients will respond fully to Clopidogrel. Patients with gene
variants that result in reduced or loss of function of CYP2C19 can
be given alternative treatments.
Programme participants include genedrive, the University of
Manchester (UoM), Health Innovation Manchester and Manchester
University NHS Foundation Trust (MFT). The DEVOTE programme will be
led by Professor William Newman, Professor of Translational Genomic
Medicine at the University of Manchester and Consultant at Saint
Mary's Hospital, part of Manchester University NHS Foundation
Trust. Additional and ongoing project information is available at
https://www.devoteprogramme.co.uk/
Professor William Newman said: " We look forward to working with
genedrive and our other DEVOTE programme colleagues in Manchester
to develop a framework for time-critical pharmacogenetics, and to
provide the framework for assessment of implementation of the
Genedrive(R) CYP2C19 ID Kit in emergency care. DEVOTE will further
establish the Manchester environ as a world recognised centre for
the development and implementation of pharmacogenomic testing."
David Budd, Chief Executive Officer of genedrive plc, said:
"DEVOTE is an amazing opportunity to engage formally with a health
system like the NHS to demonstrate the effectiveness of a new
diagnostic approach. Access to the Acute Medicine Unit in real time
has considerable value to genedrive as further funding would allow
us to progress ongoing product development quickly and efficiently,
and would support the pathway to clinical validation of our
Genedrive(R) CYP2C19 ID Kit. This level of clinical input and
evaluation is increasingly required by regulatory authorities prior
to marketing product especially in the EU. We are privileged to
continue with our partners at UoM and MFT in developing
time-critical genetic test solutions."
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Duckworth
finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Alice Lane
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com ) genedrive
plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Company has assays on the market for the detection
of MT-RNR1, HCV, certain military biological targets, a high
throughput SARS-CoV-2 assay and a point of care test for Covid-19.
The company are currently developing a genetic test for CYP2C19
metaboliser status.
About DEVOTE
The Development and Validation of Technology for Time Critical
Genomic Testing (DEVOTE) Programme is a collaboration between
academics, clinicians, and industry partners. It aims to accelerate
the adoption of genomic technology into clinical practice by
supporting companies through each aspect of the translational
pathway.
For more information contact info@devoteprogramme.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUVUORORUNAAR
(END) Dow Jones Newswires
June 16, 2023 02:00 ET (06:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024